We shoot and we score. Up 1,133% since adding to Watch List @ $3.00.
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
![](https://internetstockreview.com/wp-content/uploads/2021/11/Quote-Final-LDM-1024x503.png)
We’re so excited about the recent turn of events, we have to put an ‘Aerial Over Bermuda’ video on to relax. Better than CNBC in the background!
No kidding.
Just a brief heads up.
Novo Nordisk (NVO) is after Dicerna (DRNA), which we found four years ago with at $3.30 a share with a miniscule $68 million market cap.
Second time a mini (and client) on our Watch List is getting acquired in the last two years for over $1 billion.
RNAi therapeutic sympathy plays today include Arrowhead Pharmaceuticals (ARWR) and Alnylam Pharmaceuticals (ALNY).
Back in 2020..
We added Immunomedics (IMMU) to the Watch List in September of 2016 at $3.00, and near immediately it gapped down to $2.50. Making us wonder if the short-sellers who were short 29 million shares, knew something our boy wonder analyst did not!
Immunomedics (IMMU). $3.00 Epic Short Squeeze Inflection Point Nears.
Market Cap at the time was $288 million.
We later added it to the January 2020 5-Stocks we Expect to Double List at $18.78.
In May of 2020 at $33, we raised the ‘price potential.’ Immunomedics (IMMU) $33 | Raising Price Potential to $60.
Despite absolutely nerve wracking volatility, things worked out quite well when they were acquired for $21 billion in September of 2020 by Gilead (GILD).
Immunomedics (IMMU) $3.00 to $88, Up 29-fold, Our Second Best Idea Ever.
![](https://internetstockreview.com/wp-content/uploads/2021/11/Chart-Final-2.jpg)
![](https://internetstockreview.com/wp-content/uploads/2021/11/Chart-Final-1-1024x497.jpg)
And now Dicerna (DRNA) is getting taken out – in a good way!
We added Dicerna to the Watch List in July of 2017 at $3.00, when they were out of money and tapped out, just after Bain Capital showed up with a $70 million life line. That’s all we needed to hear. Others were calling it ‘horrible’ dilution..
Market Cap at the time was only $68 million.
Adding Dicerna (DRNA) $3.30 to Watch List.
![](https://internetstockreview.com/wp-content/uploads/2021/11/yahoo-quote.png)
![](https://internetstockreview.com/wp-content/uploads/2021/11/Chart-6-final-LT-2-1024x531.png)
We additionally added it along with Immunomedics to our 2020 5-Stocks we Expect to Double List, (which it did, twice!) despite it already being up six-fold from where we originally found it. And some don’t believe us, when we say we are long-term players…
5 Biotech Stocks We Expect to Double List
![](https://internetstockreview.com/wp-content/uploads/2021/11/2020-list.png)
While volatile, things never really looked back from 2017. Up until this August that is – when it dropped from $40 to $20 on news that its PHYOX4 study didn’t meet their endpoints. But that’s all history now.
What an air-pocket!
![](https://internetstockreview.com/wp-content/uploads/2021/11/Chart-Cahsm-1024x535.png)
Denmark’s Novo Nordisk to buy Dicerna Pharma for $3.3 billion.
But Wait, There’s More!
We just checked the overall performance of the 2020 Biotech Portfolio and we did pretty well – if we must say so ourselves.
Take a peek.
ABVC (ABVC) $3.30 to $29 up 779%
Citius Pharma (CTXR) $1.02 to $4.56 up 298%
Dicerna (DRNA) $20 to $40.14 up 100%
Dyadic (DYAI) $5.91 to $10.35 (okay close) up 75%
Fortress Bio (FBIO) $2.70 to $6.10 up 125%
Immunomedics (IMMU) $18.78 to $88 (acquired) up 222%
Those are peak prices, with no guidance (buy oe sell) from us. Six out of six winners, and five out of six gaining 100% ain’t bad right?
Of course past performance is no indication of future performance, but if you’re not a subscriber – go ahead and subscribe – it’s free.
![](https://internetstockreview.com/wp-content/uploads/2021/11/ISR-Sub-2.png)
We were compensated and/or shared in compensated positions in both IMMU and DRNA, please see individual reports for disclaimer and disclosure details.
#IMMU, #DRNA